CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Povidone-Iodine Nasal Spray and GargleWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1208 Inhaled budesonide Wiki 0.71

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.04

There are 2 clinical trials

Clinical Trials

1 Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic

Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses. It has been previously used in both intranasal preparations against Methicillin Resistant Staphylococcus Aureus (MRSA) as well as oral preparations in in-vitro studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), influenza H1N1, and rotavirus with good efficacy. This study will evaluate the efficacy of PVP-I as prophylaxis in Coronavirus Disease 2019 (COVID19)-negative front-line health care workers and hospital patients.

NCT04364802 COVID-19 SARS-CoV 2 Drug: Povidone-Iodine Nasal Spray and Gargle Drug: Povidone-Iodine Nasal Spray and Gargle

Primary Outcomes

Description: Percent of healthcare workers that become positive for COVID-19 during the study.

Measure: Percent of healthcare workers testing positive for COVID-19.

Time: 3 weeks

Description: Percent of patients that become positive for COVID-19 during the study.

Measure: Percent of patients testing positive for COVID-9.

Time: 2 weeks

Secondary Outcomes

Description: Patients will rate the ease of use for PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased ease of use (1="easy") while higher scores indicate increased difficulty (5="impossible").

Measure: PVP-I Ease of Use

Time: 3 weeks

Description: Patients will rate the comfort of PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased comfort (1="not so bad") while higher scores indicate discomfort (5="worst pain of my life").

Measure: PVP-I Comfort

Time: 3 weeks

Other Outcomes

Description: Participants will fill out a daily questionaire assessing treatment frequency. Adherence will be calculated as the percent of correct dosing.

Measure: Adherence to treatment protocol

Time: 3 weeks

2 Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic

Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses. It has been previously used in both intranasal preparations against Methicillin Resistant Staphylococcus Aureus (MRSA) as well as oral preparations in in-vitro studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), influenza H1N1, and rotavirus with good efficacy. This study will evaluate the efficacy of PVP-I as prophylaxis in Coronavirus Disease 2019 (COVID19)-negative front-line health care workers and hospital patients.

NCT04364802 COVID-19 SARS-CoV 2 Drug: Povidone-Iodine Nasal Spray and Gargle Drug: Povidone-Iodine Nasal Spray and Gargle

Primary Outcomes

Description: Percent of healthcare workers that become positive for COVID-19 during the study.

Measure: Percent of healthcare workers testing positive for COVID-19.

Time: 3 weeks

Description: Percent of patients that become positive for COVID-19 during the study.

Measure: Percent of patients testing positive for COVID-9.

Time: 2 weeks

Secondary Outcomes

Description: Patients will rate the ease of use for PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased ease of use (1="easy") while higher scores indicate increased difficulty (5="impossible").

Measure: PVP-I Ease of Use

Time: 3 weeks

Description: Patients will rate the comfort of PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased comfort (1="not so bad") while higher scores indicate discomfort (5="worst pain of my life").

Measure: PVP-I Comfort

Time: 3 weeks

Other Outcomes

Description: Participants will fill out a daily questionaire assessing treatment frequency. Adherence will be calculated as the percent of correct dosing.

Measure: Adherence to treatment protocol

Time: 3 weeks

No related HPO nodes (Using clinical trials)